Clinical Trial Update: Pharmacokinetic and Safety of GSK573719 and GW642444 Administered Individually and Concurrently, With Verapamilin in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic and safety study of GSK573719 and GW642444 administered alone and with verapamil in healthy subjects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• GSK573719
• GW642444 (GW642444)
• Verapamil (verapamil)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 1 | Status: COMPLETED